bluebird bio Inc. (BLUE)

154.30
2.10 1.34
NASDAQ : Health Technology
Prev Close 156.40
Open 155.55
Day Low/High 152.37 / 156.40
52 Wk Low/High 90.75 / 236.17
Volume 341.37K
Avg Volume 874.40K
Exchange NASDAQ
Shares Outstanding 54.16M
Market Cap 8.45B
EPS -7.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bluebird Bio To Present Updated Data For Lenti-D™ Gene Therapy For Cerebral Adrenoleukodystrophy At SSIEM 2018 Symposium

Bluebird Bio To Present Updated Data For Lenti-D™ Gene Therapy For Cerebral Adrenoleukodystrophy At SSIEM 2018 Symposium

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from its clinical development program for its investigational Lenti-D™ gene therapy in pediatric patients with cerebral adrenoleukodystrophy (CALD) will be presented at the Society for the Study of...

Bluebird Bio To Present At The 2018 Wedbush PacGrow Healthcare Conference

Bluebird Bio To Present At The 2018 Wedbush PacGrow Healthcare Conference

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the 2018 Wedbush PacGrow Healthcare Conference, Tuesday, August 14, at 8:35 a.

Bluebird Bio Reports Second Quarter 2018 Financial Results And Highlights Operational Progress

Bluebird Bio Reports Second Quarter 2018 Financial Results And Highlights Operational Progress

bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the second quarter ended June 30, 2018.

Bluebird Bio Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Bluebird Bio Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

bluebird bio, Inc. (Nasdaq: BLUE) today announced the closing of its previously announced underwritten public offering of 3,892,308 shares of its common stock, including 507,692 shares of common stock sold pursuant to the underwriters' full exercise of...

Bluebird Bio's LentiGlobin™ Gene Therapy Granted Accelerated Assessment By European Medicines Agency For The Treatment Of Transfusion-Dependent β-Thalassemia

Bluebird Bio's LentiGlobin™ Gene Therapy Granted Accelerated Assessment By European Medicines Agency For The Treatment Of Transfusion-Dependent β-Thalassemia

bluebird bio, Inc. (Nasdaq: BLUE) today announced that its investigational LentiGlobin™ gene therapy for the treatment of adolescent and adult patients with transfusion-dependent β-thalassemia (TDT) and a non-β 0/β 0 genotype, was granted an accelerated...

Trump's Trade War Against U.S. Allies Is a Direct Hit to Key Industries

Trump's Trade War Against U.S. Allies Is a Direct Hit to Key Industries

Diplomacy must precede presidential threats.

Bluebird Bio Announces Pricing Of Public Offering Of Common Stock

Bluebird Bio Announces Pricing Of Public Offering Of Common Stock

bluebird bio, Inc. (Nasdaq: BLUE) today announced the pricing of an underwritten public offering of 3,384,616 shares of its common stock at a public offering price of $162.

Bluebird Bio Announces Proposed Public Offering Of Common Stock

Bluebird Bio Announces Proposed Public Offering Of Common Stock

bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has commenced an underwritten public offering of $400 million of its common stock.

Kraft Heinz, VF Corp, Cimarex Energy: 'Mad Money' Lightning Round

Kraft Heinz, VF Corp, Cimarex Energy: 'Mad Money' Lightning Round

Jim Cramer takes a look at Kraft Heinz, VF Corp, Cimarex Energy, STORE Capital, Wheaton Precious Metals, Bluebird Bio, First Commonwealth Financial Corp.

Industrials in Value Territory: Cramer's 'Mad Money' Recap (Thursday 6/21/18)

Industrials in Value Territory: Cramer's 'Mad Money' Recap (Thursday 6/21/18)

Jim Cramer says many stocks already reflect the worst-case scenarios, and that means he sees a lot of upside potential.

Bluebird Bio Announces New Interim Data From Phase 1 (HGB-206) Study Of LentiGlobin™ Gene Therapy In Patients With Severe Sickle Cell Disease At Annual Congress Of The European Hematology Association

Bluebird Bio Announces New Interim Data From Phase 1 (HGB-206) Study Of LentiGlobin™ Gene Therapy In Patients With Severe Sickle Cell Disease At Annual Congress Of The European Hematology Association

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral...

Bluebird Bio Presents New Data From Northstar (HGB-204) And Northstar-2 (HGB-207) Studies Of LentiGlobin™ Gene Therapy In Patients With Transfusion-Dependent β-Thalassemia At Annual Congress Of The European Hematology Association

Bluebird Bio Presents New Data From Northstar (HGB-204) And Northstar-2 (HGB-207) Studies Of LentiGlobin™ Gene Therapy In Patients With Transfusion-Dependent β-Thalassemia At Annual Congress Of The European Hematology Association

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207)...

Bluebird Bio Announces Investor Events In June

Bluebird Bio Announces Investor Events In June

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in June: Jefferies Global Healthcare Conference, Thursday, June 7, at 10:00 a.

FDA Grants Breakthrough Therapy Designation To Lenti-D™ For The Treatment Of Cerebral Adrenoleukodystrophy

FDA Grants Breakthrough Therapy Designation To Lenti-D™ For The Treatment Of Cerebral Adrenoleukodystrophy

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.

Bluebird Bio To Present New Data From LentiGlobinTM Transfusion-Dependent β-Thalassemia And Severe Sickle Cell Disease Clinical Studies At Annual Congress Of The European Hematology Association

Bluebird Bio To Present New Data From LentiGlobinTM Transfusion-Dependent β-Thalassemia And Severe Sickle Cell Disease Clinical Studies At Annual Congress Of The European Hematology Association

bluebird bio, Inc. ( Nasdaq: BLUE) announced that data from ongoing LentiGlobin clinical studies in transfusion-dependent ß-thalassemia (TDT) and severe sickle cell disease (SCD) will be highlighted in oral presentations at the 23 rd Congress of the...

Bluebird Bio To Present Updated Clinical Results From Ongoing Multicenter Phase 1 Study Of Bb2121 Anti- BCMA CAR T Cell Therapy In Patients With Late Stage Relapsed/Refractory Multiple Myeloma At ASCO Annual Meeting

Bluebird Bio To Present Updated Clinical Results From Ongoing Multicenter Phase 1 Study Of Bb2121 Anti- BCMA CAR T Cell Therapy In Patients With Late Stage Relapsed/Refractory Multiple Myeloma At ASCO Annual Meeting

bluebird bio, Inc. ( Nasdaq: BLUE) announced that updated interim data from CRB-401, its Phase 1 study of bb2121, an anti-BCMA CAR T cell therapy being developed by the company and Celgene, will be presented at the American Society of Clinical Oncology...

Chart of the Day: BLUE

The setup on bluebird bio is nice, with the stock overbought but not yet overheated.

Bluebird Bio To Present At Investor Conferences In May

Bluebird Bio To Present At Investor Conferences In May

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: Deutsche Bank's 43 rd Annual Health Care Conference, Wednesday, May 9, at 10:00 a.

Bluebird Bio Reports First Quarter 2018 Financial Results And Highlights Operational Progress

Bluebird Bio Reports First Quarter 2018 Financial Results And Highlights Operational Progress

bluebird bio, Inc. (Nasdaq: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2018.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Here's what you need to know for Monday, April 9.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Celgene Shares Higher on Co-Development Pact With Bluebird

Celgene Shares Higher on Co-Development Pact With Bluebird

The biotech firms will work to develop and promote a potential treatment for relapsed and refractory multiple myeloma.

Bluebird Bio And Celgene Corporation Enter Into Agreement To Co-Develop And Co-Promote Anti-BCMA CAR T Cell Therapy Bb2121 In The United States

Bluebird Bio And Celgene Corporation Enter Into Agreement To Co-Develop And Co-Promote Anti-BCMA CAR T Cell Therapy Bb2121 In The United States

bluebird bio, Inc. (Nasdaq: BLUE) and Celgene Corporation (Nasdaq: CELG) today announced that the companies have entered into an agreement to co-develop and co-promote bb2121, an investigational anti-B-cell...

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

Bluebird Bio To Present At Investor Conferences In March

Bluebird Bio To Present At Investor Conferences In March

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced...

Bluebird Bio Reports Fourth Quarter And Full Year 2017 Financial Results And Highlights Operational Progress

Bluebird Bio Reports Fourth Quarter And Full Year 2017 Financial Results And Highlights Operational Progress

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today reported...

TheStreet Quant Rating: D+ (Sell)